tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2018-96-11-74-82tiblj-1197Research ArticleОБЗОРЫREVIEWSПерспективы применения таргетной химиотерапии деламанидом в схемах лечения больных туберкулезом с множественной/широкой лекарственной устойчивостью возбудителя. Успехи, возможности или неопределенность?Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty?НаумовА. Г.NaumovAleksey G.

ассистент кафедры фтизиатрии им. И. С. Николаева.603093, г. Нижний Новгород, ул. Родионова, д. 198.

Assistant of I.S. Nikolaev Phthisiology Department198, Rodionova St., Nizhny Novgorod, 603093

naumovag@nizhgma.ruПавлунинА. В.PavluninAleksandr V.

доктор медицинских наук, профессор, заведующий кафедрой фтизиатрии им. И. С. Николаева.603093, г. Нижний Новгород, ул. Родионова, д. 198.

Doctor of Medical Sciences, Professor, Head of I.S. Nikolaev Phthisiology Department.198, Rodionova St., Nizhny Novgorod, 603093

pavluninav@yandex.ruФГБОУ ВО «Приволжский исследовательский медицинский университет» МЗ РФРоссияPrivolzhskiy Research Medical UniversityRussian Federation20182311201896117482Copyright © Наумов А.Г., Павлунин А.В., 20182018Наумов А.Г., Павлунин А.В.Naumov A.G., Pavlunin A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1197

Представлен обзор современных статей, клинических рекомендаций и руководств (гайдлайнов) зарубежных авторов, посвященных проблеме лечения туберкулеза с лекарственной устойчивостью возбудителя, с использованием препарата деламанид. В источниках представлены сведения о высокой эффективности деламанида при его использовании в комбинации с другими противотуберкулезными препаратами для лечения больных МЛУ-туберкулезом органов дыхания – у 74,5% пациентов к завершению 6-месячного курса терапии удалось добиться полного прекращения бактериовыделения.

The article presents the review of current publications, clinical recommendations and guidelines written by foreign authors and devoted to treatment of drug resistant tuberculosis with delamanid. According to the publications, delamanid and its combinations with other anti-tuberculosis are highly effective when used for treatment of respiratory MDR tuberculosis: 74.5% of patients achieved the complete sputum conversion by the 6th month of treatment.

туберкулезШЛУ-туберкулезМЛУ-туберкулезделаманидхимиотерапияtuberculosisXDR tuberculosisMDR tuberculosisdelamanidchemotherapyReferencesВасильева И. А. и др. Заболеваемость, смертность и распространенность как показатели бремени туберкулеза в регионах ВОЗ, странах мира и в Российской Федерации. Часть 1. Заболеваемость и распространенность туберкулеза // Туб. и болезни легких. – 2017. – Т. 95, № 6. – С. 9-21.Vasilyeva I.A. et al. Incidence, mortality and prevalence as indicators of tuberculosis burden in WHO regions, countries of the world, and the Russian Federation. Part 1. Tuberculosis incidence and prevalence. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 6, pp. 9-21. (In Russ.)Нечаева О. Б. Аналитический обзор ситуации по туберкулезу в России в 2016 году. – М., 2016. – 69 с.Nechaeva O.B. Аnaliticheskiy obzor situatsii po tuberkulezu v Rossii v 2016 godu. [Analytic review of tuberculosis situation in Russia in 2016]. Moscow, 2016, 69 p.Нечаева О. Б. Аналитический обзор основных статистических показателей по туберкулезу в России. – М., 2017. – 4 с.Nechaeva O.B. Analitichesky obzor osnovnykh statisticheskhy pokazateley po tuberkulezu v Rossii. [Analytic review of main tuberculosis statistic rates used in Russia]. Moscow, 2017, 4 p.Ahuja S. D., Ashkin D., Avendano M. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients // PLoS Med. – 2012. – Vol. 9. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/22952439. – Date of access: 19.03.2018.Ahuja S.D., Ashkin D., Avendano M. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLos Med., 2012, vol. 9, Available at: https://www.ncbi.nlm.nih.gov/pubmed/22952439. Accessed: 19.03.2018.Barry P. J., O’Connor T. M. Novel agents in the management of Mycobacterium tuberculosis disease // Curr. Med. Chemistry. – 2007. – Vol. 14, № 18. – P. 2000-2008.Barry P.J., O’Connor T.M. Novel agents in the management of Mycobacterium tuberculosis disease. Curr. Med. Chemistry, 2007, vol. 14, no. 18, pp. 2000-2008.Bonnet M., Bastard M., du Cros P. et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR TB cohort study // Intern. J. Tub. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease. – 2016. – Vol. 20, № 2. – P. 177-186.Bonnet M., Bastard M., du Cros P. et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR TB cohort study. Intern. J. Tub. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease, 2016, vol. 20, no. 2, pp. 177-186.Borisov S. E., Dheda K., Enwerem M. et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study // Eur. Respir. J. – 2017. – Vol. 49, № 5. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/28529205. – Date of access: 01.04.2018.Borisov S.E., Dheda K., Enwerem M. et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur. Respir. J., 2017, vol. 49, no. 5, Available at: https://www.ncbi.nlm.nih.gov/pubmed/28529205. Accessed: 01.04.2018.Brigden G., Hewison C., Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid // Infect. Drug Resist. – 2015. – № 8. – P. 367-378.Brigden G., Hewison C., Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect. Drug Resist. 2015, no. 8, pp. 367-378.Budha N. R. A Pharmacokinetics and pharmacodynamics (PK/PD) guided approach to lead optimization of nitrofuranylamide anti-tuberculosis agents // Theses and Dissertations (ETD). – 2009. – Vol. 5. – P. 30-33.Budha N.R. A Pharmacokinetics and pharmacodynamics (PK/PD) guided approach to lead optimization of nitrofuranylamide anti-tuberculosis agents. Theses and Dissertations (ETD), 2009, vol. 5, pp. 30-33.Byun J. H., Park J. A., Kang H. R. et al. Comparison of effectiveness between delamanid and bedaquiline among patients with multidrug-resistant tuberculosis: a Markov model simulation study // Clin. Drug Investig. – 2016. – Vol. 36, № 11. – P. 957-968.Byun J.H., Park J.A., Kang H.R. et al. Comparison of effectiveness between delamanid and bedaquiline among patients with multidrug-resistant tuberculosis: a Markov model simulation study. Clin. Drug Investig., 2016, vol. 36, no. 11, pp. 957-968.Conradie F., Meintjes G., Hughes J. et al. Clinical Access to bedaquiline programme of drug-resistant tuberculosis // South African Med. J. – 2014. – Vol. 104, № 3. – P. 164-166.Conradie F., Meintjes G., Hughes J. et al. Clinical Access to bedaquiline programme of drug-resistant tuberculosis. South African Med. J., 2014, vol. 104, no. 3, pp. 164-166.Cox H. S., Furin J. J., Mitnick C. D. et al. The need to accelerate access to new drugs for multidrug-resistant tuberculosis // Bulletin of the World Health Organization. – 2015. – Vol. 93, № 7. – P. 491-497.Cox H.S., Furin J.J., Mitnick C.D. et al. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bulletin of the World Health Organization, 2015, vol. 93, no. 7, pp. 491-497.Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells // Natur. Rev. Microbiol. – 2014. – № 12. – P. 159-167.Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Natur. Rev. Microbiol., 2014, no. 12, pp. 159-167.Dedicoat M. Using bedaquiline and delamanid in combination and safety // Intern. J. Tuberc. Lung Dis: the official journal of the International Union against Tuberculosis and Lung Disease. – 2016. – Vol. 20, № 10. – P. 1282.Dedicoat M. Using bedaquiline and delamanid in combination and safety. Intern. J. Tuberc. Lung Dis: the official journal of the International Union against Tuberculosis and Lung Disease, 2016, vol. 20, no. 10, pp. 1282.Delamanid [Electronic resource]. – Mode of access: http://www.chemspider.com/Chemical-Structure.4981055.html. – Date of access: 10.04.2018.Delamanid [Electronic resource]. Available at: http://www.chemspider.com/Chemical-Structure.4981055.html. Accessed: 10.04.2018.Diacon A. H., Dawson R., Hanekom M. et al. Early bacterial activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients // Internat. J. Tuberc. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease. – 2011. – Vol. 15, № 7. – P. 949-954.Diacon A.H., Dawson R., Hanekom M. et al. Early bacterial activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Internat. J. Tuberc. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease, 2011, vol. 15, no. 7, pp. 949-954.Diacon A. H., Pym A., Grobusch M. P. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline // New Engl. J. Med. – 2014. – Vol. 371, № 8. – P. 723-732.Diacon A.H., Pym A., Grobusch M.P. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. New Engl. J. Med., 2014, vol. 371, no. 8, pp. 723-732.Diacon A.H., von Groote-Bidlingmaier F., Delamanid P. R. D. A new 6-nitro-2,3-dihydroimidazo[2,1-b] oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin // Expert Opinion on Orphan Drugs. – 2014. – Vol. 2, № 1. – P. 87-94.Diacon A.H., von Groote-Bidlingmaier F., Delamanid P.R.D. A new 6-nitro-2,3-dihydroimidazo[2,1-b] oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin. Expert Opinion on Orphan Drugs, 2014, vol. 2, no. 1, pp. 87-94.Diel R., Hittel N., Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba to background regimens in Germany // Respir. Med. – 2015. – Vol. 109, № 5. – P. 632-641.Diel R., Hittel N., Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba to background regimens in Germany. Respir. Med., 2015, vol. 109, no. 5, pp. 632-641.Diel R., Nienhaus A., Lampenius N. et al. Cost of multi drug resistance tuberculosis in Germany // Respir. Med. – 2014. – Vol. 108, № 11. – P. 1677-1687.Diel R., Nienhaus A., Lampenius N. et al. Cost of multi drug resistance tuberculosis in Germany. Respir. Med., 2014, vol. 108, no. 11, pp. 1677-1687.European Medicines Agency. Assessment Report: Deltyba. London: European Medicines Agency. – 2013. – 140 p.European Medicines Agency. Assessment Report: Deltyba. London, European Medicines Agency. 2013, 140 p.European Medicines Agency. Summary of product characteristics. Deltyba. Otsuka Novel Products GmbH. European Medicines Agency. – 2014. – P. 2-29.European Medicines Agency. Summary of product characteristics. Deltyba. Otsuka Novel Products GmbH. European Medicines Agency. 2014, pp. 2-29.Falzon D., Nhat N. L., Ernesto J., Karin W. The global response to rifampicin-resistant tuberculosis: current situation and recent trends // Europ. Respir. J. – 2016. – Vol. 48, № 60. – P. 1903.Falzon D., Nhat N.L., Ernesto J., Karin W. The global response to rifampicin-resistant tuberculosis: current situation and recent trends. Europ. Respir. J., 2016, vol. 48, no. 60, pp. 1903.Falzon D., Schunemann H. J., Harausz E. et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update // Europ. Respir. J. – 2017. – Vol. 49, № 3. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/28331043. – Date of access: 01.03.2018.Falzon D., Schunemann H.J., Harausz E. et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Europ. Respir. J., 2017, vol. 49, no. 3, Available at: https://www.ncbi.nlm.nih.gov/pubmed/28331043. Accessed: 01.03.2018.Ferlazzo G. et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study // Lancet Infect. Dis. – 2018. – P. 1-9. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/29452942. – Date of access: 19.03.2018.Ferlazzo G. et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect. Dis., 2018, pp. 1-9. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29452942. Accessed: 19.03.2018.Gler M. T., Skripconoka V., Sanchez-Garavito E. et al. Delamanid for multidrug-resistant pulmonary tuberculosis // New Engl. J. Med. – 2012. – Vol. 366, № 23. – P. 2151-2160.Gler M.T., Skripconoka V., Sanchez-Garavito E. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. New Engl. J. Med., 2012, vol. 366, no. 23, pp. 2151-2160.Global tuberculosis report 2017. – Geneva: World Health Organization, 2017. – 147 p.Global tuberculosis report 2017. Geneva, World Health Organization, 2017, 147 p.Gruber K. Access sought to tuberculosis drug from nutraceutical company // Nature medicine. – 2015. – Vol. 21, № 2. – P. 103.Gruber K. Access sought to tuberculosis drug from nutraceutical company. Nature Medicine, 2015, vol. 21, no. 2, pp. 103.Guglielmetti L., Du D. L., Jachym M. et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort // Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. – 2015. – Vol. 60, № 2. – P. 188-194.Guglielmetti L., Du D.L., Jachym M. et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2015, vol. 60, no. 2, pp. 188-194.Gupta R., Geiter L. J., Wells C. D. et al. Delamanid for extensively drug-resistant tuberculosis // New Engl. J. Med. – 2015. – Vol. 373, № 3. – P. 291-292.Gupta R., Geiter L.J., Wells C.D. et al. Delamanid for extensively drug-resistant tuberculosis. New Engl. J. Med., 2015, vol. 373, no. 3, pp. 291-292.Harausz E. P., Garcia-Prats A., Seddon J. A. et al. New drugs, repurposed drugs, and novel regimens for children with multidrug-resistant tuberculosis: practice-based recommendations // Am. J. Respir. Crit. Care Med. – 2017. – Vol. 195, № 10. – Mode of access: https://www.atsjournals.org/doi/abs/10.1164/rccm.201606-1227CI?journalCode=ajrccm. – Date of access: 01.03.2018.Harausz E.P., Garcia-Prats A., Seddon J.A. et al. New drugs, repurposed drugs, and novel regimens for children with multidrug-resistant tuberculosis: practice-based recommendations. Am. J. Respir. Crit. Care Med., 2017, vol. 195, no. 10, Available at: https://www.atsjournals.org/doi/abs/10.1164/rccm.201606-1227CI?journalCode=ajrccm. Accessed: 01.03.2018.Horsburgh C. R. Jr., Haxaire-Theeuwes M., Lienhardt C. et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis // The international journal of tuberculosis and lung disease: the official journal of the International Union against. – 2013. – Vol. 17, № 2. – P. 146-152.Horsburgh C.R.Jr., Haxaire-Theeuwes M., Lienhardt C. et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. The international journal of tuberculosis and lung disease: the official journal of the International Union against, 2013, vol. 17, no. 2, pp. 146-152.Lachatre M., Rioux C., Du D. L. et al. Bedaquiline plus delamanid for XDR tuberculosis // Lancet. Infect. Dis. – 2016. – Vol. 16, № 3. – P. 294.Lachatre M., Rioux C., Du D.L. et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet. Infect. Dis., 2016, vol. 16, no. 3, pp. 294.Lewis M. J. et al. The role of delamanid in the treatment of drug-resistant tuberculosis // Therap. Clin. Risk Management. – 2015. – Vol. 11. – P. 779-791.Lewis M.J. et al. The role of delamanid in the treatment of drug-resistant tuberculosis. Therap. Clin. Risk Management, 2015, vol. 11, pp. 779-791.Lienhardt C., Nahid P., Rich M. L. et al. Target regimen profiles for treatment of tuberculosis: A WHO document // Europ. Respir. J. – 2017. – Vol. 49. – Mode of access: http://erj.ersjournals.com/content/49/1/1602352. – Date of access: 01.03.2018.Lienhardt C., Nahid P., Rich M.L. et al. Target regimen profiles for treatment of tuberculosis: A WHO document. Europ. Respir. J., 2017, vol. 49. Accessed: http://erj.ersjournals.com/content/49/1/1602352. Accessed: 01.03.2018.Ma Z., Lienhardt C., McIlleron H. et al. Global tuberculosis drug development pipeline: the need and the reality // Lancet. – 2010. – Vol. 375, № 9731. – P. 2100-2109.Ma Z., Lienhardt C., McIlleron H. et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet, 2010, vol. 375, no. 9731, pp. 2100-2109.Matsumoto M., Hashizume H., Tomishige T. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice // PLoS Med. – 2006. – Vol. 9, № 11 – P. 2131-2144.Matsumoto M., Hashizume H., Tomishige T. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLos Med., 2006, vol. 9, no. 11, pp. 2131-2144.Matteelli A., D’Ambrosio L., Centis R. Compassionate and optimum use of new tuberculosis drugs // Lancet. Infect Dis. – 2015. – Vol. 15, № 10. – P. 1131-1132.Matteelli A., D’Ambrosio L., Centis R. Compassionate and optimum use of new tuberculosis drugs. Lancet. Infect Dis., 2015, vol. 15, no. 10, pp. 1131-1132.Migliori G. B. et al. Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: a systematic review // Internat. J. Molecul. Sci. – 2017. – Vol. 18, № 2. – Mode of access: https://www.ncbi.nlm.nih.gov/pubmed/28178199. – Date of access: 01.04.2018.Migliori G.B. et al. Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: a systematic review. Internat. J. Molecul. Sci., 2017, vol. 18, no. 2, Available at: https://www.ncbi.nlm.nih.gov/pubmed/28178199. Accessed: 01.04.2018.Migliori G. B., Eker B., Richardson M. D. et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis // Eur. Respir. J. – 2009. – Vol. 34, № 2. – P. 387-393.Migliori G.B., Eker B., Richardson M.D. et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J., 2009, vol. 34, no. 2, pp. 387-393.Millikaarjun S., Wells C., Petersen C. Delamanid coadministred with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects // Antimicrob. Agents Chemother. – 2016. – Vol. 60, № 10. –P. 5976-5985.Millikaarjun S., Wells C., Petersen C. Delamanid coadministred with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob. Agents Chemother., 2016, vol. 60, no. 10, pp. 5976-5985.Mukherjee T., Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future // Future Med. Chemistry. – 2011. – Vol. 3, № 11. – P. 1427-1454.Mukherjee T., Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. Future Med. Chemistry, 2011, vol. 3, no. 11, pp. 1427-1454.Mullerpattan B. J., Udwadia Z. F. Bedaquiline and Delamanid: Sharing the Indian Experience // Actrocyte. – 2017. – Vol. 4. – P. 108-110.Mullerpattan B.J., Udwadia Z.F. Bedaquiline and Delamanid: Sharing the Indian Experience. Actrocyte, 2017, vol. 4. pp. 108-110.Ndjeka N., Conradie F., Schippel K. et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis // Intern. J. Tub. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease. – 2015. – Vol. 19, № 8. – P. 979-985.Ndjeka N., Conradie F., Schippel K. et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Intern. J. Tub. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease, 2015, vol. 19, no. 8, pp. 979-985.Nuermberger E. L., Spigelman M. K., Yew W. W. Current development and future prospects in chemotherapy of tuberculosis // Respirology. – 2010. – Vol. 15, № 5. – P. 764-778.Nuermberger E.L., Spigelman M.K., Yew W.W. Current development and future prospects in chemotherapy of tuberculosis. Respirology, 2010, vol. 15, no. 5, pp. 764-778.Olaru I. D., von Groote-Bidlingmaier F., Heyckendorf J., Yew W. W. et al. Novel drugs against tuberculosis: a clinician’s perspective // Europ. Resp. J. – 2015. – Vol. 45, № 4. – P. 1119-1131.Olaru I.D., von Groote-Bidlingmaier F., Heyckendorf J., Yew W.W. et al. Novel drugs against tuberculosis: a clinician’s perspective. Europ. Resp. J., 2015, vol. 45, no. 4, pp. 1119-1131.Pontali E., Sotgiu G., D’Ambrosio L. et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence // Eur. Respir. J. – 2016. – Vol. 47, № 2. – P. 394-402.Pontali E., Sotgiu G., D’Ambrosio L. et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur. Respir. J., 2016, vol. 47, no. 2, pp. 394-402.Rustomjee R., Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis // Infect. Drug Resist. – 2015. – Vol. 8. – P. 359-366.Rustomjee R., Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Infect. Drug Resist., 2015, vol. 8, pp. 359-366.Ryan N. J., Lo J. H. Delamanid: first global approval // Drugs. ‒ 2014. – Vol. 74, № 9. – P. 1041-1045.Ryan N.J., Lo J.H. Delamanid: first global approval. Drugs, 2014, vol. 74, no. 9, pp. 1041-1045.Saliu O. Y., Crismale C. et al. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis // J. Antimicrob. Chemother. – 2007. – Vol. 60, № 5. – P. 994-998.Saliu O.Y., Crismale C. et al. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J. Antimicrob. Chemother., 2007, vol. 60, no. 5, pp. 994-998.Sasahara K., Shimokawa Y., Hirao Y. et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo // Drug Metabolism and Disposition: the biological fate of chemicals. – 2015. – Vol. 43, № 8. – P. 1267-1276.Sasahara K., Shimokawa Y., Hirao Y. et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. Drug Metabolism and Disposition: the biological fate of chemicals, 2015, vol. 43, no. 8, pp. 1267-1276.Sasaki H., Haraguchi Y., Itotani M. et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b] oxazoles // J. Med. Chemistry. – 2006. – Vol. 29, № 26. – P. 7854-7860.Sasaki H., Haraguchi Y., Itotani M. et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b] oxazoles. J. Med., Chemistry, 2006, vol. 29, no. 26, pp. 7854-7860.Shan N. S. et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa // Emerg. Infect. Dis. – 2011. ‒ Vol. 17, № 3. – P. 510-513.Shan N.S. et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg. Infect. Dis., 2011, vol. 17, no. 3, pp. 510-513.Shimokawa Y., Sasahara K., Koyama N. et al. Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma // Drug Metabol. Disposit: the biological fate of chemicals. – 2015. – Vol. 43, № 8. – P. 1277-1283.Shimokawa Y., Sasahara K., Koyama N. et al. Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma. Drug Metabol. Disposit: the biological fate of chemicals, 2015, vol. 43, no. 8, pp. 1277-1283.Shimokawa Y., Sasahara K., Yoda N. et al. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro // Biological & pharmaceutical bulletin. – 2014. – Vol. 37, № 11. – P. 1727-1735.Shimokawa Y., Sasahara K., Yoda N. et al. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biological & Pharmaceutical Bulletin, 2014, vol. 37, no. 11, pp. 1727-1735.Singla R. Drug-resistant tuberculosis: key strategies for a recalcitrant disease // Actrocyte. – 2017. – Vol. 4, №1. – P. 53-62.Singla R. Drug-resistant tuberculosis: key strategies for a recalcitrant disease. Actrocyte, 2017, vol. 4, no. 1, pp. 53-62.Skripconoka V., Danilovits M., Pehme L. et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis // Europ. Respir. J. – 2013. – Vol. 41, № 6. – P. 1393-1400.Skripconoka V., Danilovits M., Pehme L. et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Europ. Respir. J., 2013, vol. 41, no. 6, pp. 1393-1400.Sloan D. J., Lewis J. M. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings // Transact. Royal Society Trop Med. Hygiene. – 2016. – Vol. 110, № 3. – P. 163-172.Sloan D.J., Lewis J.M. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Transact. Royal Society Trop Med. Hygiene, 2016, vol. 110, no. 3, pp. 163-172.Sotgiu G., Pontali E., Centis R. et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis // Expert Rev. Anti-Infective Therapy. – 2015. – Vol. 13, № 3. – P. 305-315.Sotgiu G., Pontali E., Centis R. et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev. Anti-Infective Therapy, 2015, vol. 13, no. 3, pp. 305-315.Sotgiu G., Pontali E., Centis R. et al. New anti-tuberculosis drugs for special populations: A difficult-to-address issue // Europ. Respir. J. – 2016. – Vol. 48, № 3. – P. 957-958.Sotgiu G., Pontali E., Centis R. et al. New anti-tuberculosis drugs for special populations: A difficult-to-address issue. Europ. Respir. J., 2016, vol. 48, no. 3, pp. 957-958.Sotgiu G., Tiberi S., D’Ambrosio L. et al. Faster for less, the new “Shorter” regimen for multidrug-resistant tuberculosis // Eur. Respir. J. – 2016. – Vol. 48, № 5. – P. 1503-1507.Sotgiu G., Tiberi S., D’Ambrosio L. et al. Faster for less, the new “Shorter” regimen for multidrug-resistant tuberculosis. Eur. Respir. J., 2016, vol. 48, no. 5, pp. 1503-1507.Stinson K. et al. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration // Antimicrob. Agents Chemother. – 2016. – Vol. 60, № 6. – P. 3316-3322.Stinson K. et al. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration. Antimicrob. Agents Chemother., 2016, vol. 60, no. 6, pp. 3316-3322.Stover C. K., Warrener P., VanDevanter D. R. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis // Nature. – 2000. – Vol. 405, № 6789. – P. 962-966.Stover C.K., Warrener P., VanDevanter D.R. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, vol. 405, no. 6789, pp. 962-966.Szumowski D. J. et al. Profile of delamanid for the treatment of multidrug-resistant tuberculosis // Drug Design, Devel. Therapy. – 2015. – Vol. 9. – P. 677-682.Szumowski D.J. et al. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Design, Devel. Therapy, 2015, vol. 9. pp. 677-682.Tadolini M., Lingsang R. D., Tiberi S. et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline // Europ. Respir. J. – 2016. – Vol. 48, № 3. – P. 935-938.Tadolini M., Lingsang R.D., Tiberi S. et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Europ. Respir. J., 2016, vol. 48, no. 3, pp. 935-938.The selection and use of essential medicine report. – Geneva: World Health Organization, 2015. – 546 p.The selection and use of essential medicine report. Geneva, World Health Organization, 2015, 546 p.The use of Bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. – Geneva: World Health Organization, 2013. – 57 p.The use of Bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva, World Health Organization, 2013, 57 p.The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. – Geneva: World Health Organization, 2014. – 65 p.The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva, World Health Organization, 2014, 65 p.The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. – Geneva: World Health Organization, 2016. – 48 p.The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. Geneva, World Health Organization, 2016, 48 p.Tiberi S., D’Ambrosio L., de Lorenzo S. et al. Tuberculosis elimination, patients’ lives and rational use of new drugs: revisited // Eur. Respir. J. – 2016. – Vol. 47, № 2. – P. 664-667.Tiberi S., D’Ambrosio L., de Lorenzo S. et al. Tuberculosis elimination, patients’ lives and rational use of new drugs: revisited. Eur. Respir. J., 2016, vol. 47, no. 2, pp. 664-667.Tiberi S., Scardigli A., Centis R. et al. Classifying new anti-TB drugs: rationale and future perspectives // Intern. J. Infect. Dis. – 2017. – Vol. 56. – P. 181-184.Tiberi S., Scardigli A., Centis R. et al. Classifying new anti-TB drugs: rationale and future perspectives. Intern. J. Infect. Dis., 2017, vol. 56. pp. 181-184.Treatment guidelines for drug-resistant tuberculosis 2016 Update. – Geneva, Switzerland: World Health Organization, 2016. – 56 p.Treatment guidelines for drug-resistant tuberculosis 2016 Update. Geneva, Switzerland, World Health Organization, 2016, 56 p.Udwadia Z. F. Totally drug-resistant tuberculosis in India: who let the djinn out? // Respirology. – 2012. – Vol. 17, № 5. – P. 741-742.Udwadia Z.F. Totally drug-resistant tuberculosis in India: who let the djinn out? Respirology, 2012, vol. 17, no. 5, pp. 741-742.Vassell A. Cost-effectiveness of introducing bedaquiline in MDR-TB regimens ‒ an exploratory analysis. – Geneva: World Health Organization, 2013. – 30 p.Vassell A. Cost-effectiveness of introducing bedaquiline in MDR-TB regimens ‒ an exploratory analysis. Geneva, World Health Organization, 2013, 30 p.Velayati A. A. et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran // Chest. – 2009. – Vol. 136, № 2. – P. 420-425.Velayati A.A. et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest, 2009, vol. 136, no. 2, pp. 420-425.Wallis R. S. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine // Eur. Respir. J. – 2016. – Vol. 48, № 5. – P. 1526-1527.Wallis R.S. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur. Respir. J., 2016, vol. 48, no. 5, pp. 1526-1527.Wirth D. et al. Cost-effectiveness of adding novel or group 5 inerventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany // BMC Health Services Research. – 2017. – Vol. 17, № 182. – P. 1-11.Wirth D. et al. Cost-effectiveness of adding novel or group 5 inerventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Services Research, 2017, vol. 17, no. 182, pp. 1-11.Wolfson L. J., Gibbert J., Wirth D., Diel R. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for multidrug-resistant/extensively drug-resistant tuberculosis in Germany // Eur. Respir. J. – 2015. – Vol. 46, № 6. – P. 1826-1829.Wolfson L.J., Gibbert J., Wirth D., Diel R. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for multidrug-resistant/extensively drug-resistant tuberculosis in Germany. Eur. Respir. J., 2015, vol. 46, no. 6, pp. 1826-1829.Zhang Q., Liu Y., Tang S. et al. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China // Cell Biochem. Biophys. – 2013. – Vol. 67, № 3. – P. 957-963.Zhang Q., Liu Y., Tang S. et al. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem. Biophys., 2013, vol. 67, no. 3, pp. 957-963.

The authors declare that there are no conflicts of interest present.